However, random allocation to canakinumab, a drug that inhibits IL-1β and reduces both IL-6 and hsCRP, did not reduce the development of incident hypertension nor reduce blood pressure at 3, 6, or 12 months. This evidence concerns the gene IL6 and hypertensive disorder.